Estimated read time: 3-4 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK] OTC-PINK:CBIS OTC-QB:CBIS
[IN] HEA SPM MTC PHA OTC
[SU] CXP LEG
TO BUSINESS, HEALTH, AND RETAILING EDITORS:
Cannabis Science Applauds Extending Legalization of Nevada Medical
Cannabis Program and Continued Growth of the U.S. Industry; Examines
Opportunities Presented by the Opening of the Nevada Market
COLORADO SPRINGS, Colo., April 4, 2014 /PRNewswire/ -- Cannabis
Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis
formulation-based drug development and related consulting is proud to
announce plans to enter the State of Nevada where new law expands
medical cannabis opportunities to research, grows, and dispensaries.
As the Company has created a partnership in Michigan to advance state
cannabis law and pursue state-wide initiatives in Michigan, Cannabis
Science intends to bring its know how and resources to Nevada, the
state of Cannabis Science's Incorporation.
The new law marks another milestone in the progression in the
legalization process of the medical cannabis industry in the United
States -- one that is aimed at ways of managing multiple ailments for
patients. In addition, the new law is expected to contribute to the
creation of new sources of revenue and employment opportunities within
the state. Cannabis Science is well positioned to bring novel
patient-based initiatives to Nevada.
"Nevada is another key state in which we, as Nevada incorporate
company, can deliver cannabis-based products and medical care to
patients. As Nevada legislation continues to develop, our Michigan
state-based experience puts Cannabis Science in an advantageous
position to develop new opportunities in Nevada," stated Dr. Dorothy
Bray, Director and CEO of Cannabis Science, Inc.
Nevada originally introduced their medical cannabis program on a
patient level in 2001. The new law, effective as of April 1, 2014,
allows for the buying, selling, and testing of cannabis as regulated,
and the taxation of cannabis revenues. Licenses for these types of
businesses will be issued, and patients can expect doors to open
around January 1, 2015.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of
metabolic processes to provide novel treatment approaches to a number
of illnesses for which current treatments and understanding remain
unsatisfactory. Cannabinoids have an extensive history dating back
thousands of years, and currently there are a growing number of
peer-reviewed scientific publications that document the underlying
biochemical pathways that cannabinoids modulate. The Company works
with leading experts in drug development, medicinal characterization,
and clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is on
skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Act of 1934. A statement containing words such as
"anticipate," "seek," intend," "believe," "estimate," "expect,"
"project," "plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results anticipated
by these forward-looking statements may not occur. Factors that could
cause or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc., does not undertake any
duty nor does it intend to update the results of these forward-looking
statements.
Cannabis Science, Inc. Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com dorothy.bray@cannabisscience.com
info@cannabisscience.com Tel: 1.888.777.0658
Investment Inquiries Robert Kane, CFO & Director
robert.kane@cannabisscience.com 561.420.4824
SOURCE Cannabis Science, Inc.
-0- 04/04/2014
/Web Site: http://www.cannabisscience.com
(OTC-PINK:CBIS /
OTC-QB:CBIS) /
CO: Cannabis Science, Inc.
ST: Colorado Nevada
IN: HEA SPM MTC PHA OTC
SU: CXP LEG
PRN
-- LA98481 --
0000 04/04/2014 14:20:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
